Search

Your search keyword '"Ligand Pharmaceuticals Inc."' showing total 4,033 results
Start Over Descriptor "Ligand Pharmaceuticals Inc."
4,033 results on '"Ligand Pharmaceuticals Inc."'

151. LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-September 4, 2023--LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4) (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 01092023 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced [...]

Published
2023

152. Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Subjects
Ligand Pharmaceuticals Inc., Stock options, Compensation management, Business, Business, international
Abstract

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand's Board of Directors granted non-qualified stock [...]

Published
2023

153. Slone Partners Places Christophe Arbet-Engels as Chief Medical Officer at X4 Pharmaceuticals

Subjects
Ligand Pharmaceuticals Inc., Merck Research Laboratories, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

New CMO brings more than 20 years of experience in complex organizational settings SOUTH RIDING, Va., Aug. 31, 2023 /PRNewswire-PRWeb/ -- https://c212.net/c/link/?t=0&l=en&o=3957009-1&h=363047404&u=http%3A%2F%2Fwww.slonepartners.com%2F&a=Slone+Partners, a nationwide executive search firm for life sciences, [...]

Published
2023

154. NCLA requests that the Supreme Court hear an important first amendment appeal involving securities law

Subjects
United States. Supreme Court, Ligand Pharmaceuticals Inc., Publicly held corporations, Securities law, Fraud, Appellate procedure, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Washington, D.C: The New Civil Liberties Alliance has filed a petition for a writ of certiorari in Lemelson, et al. v. SEC, asking the U.S. Supreme Court to hear a [...]

Published
2023

155. Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

Subjects
Ligand Pharmaceuticals Inc., Bankruptcy reorganizations, Pharmaceutical industry, Company bankruptcy, General interest, News, opinion and commentary
Abstract

DURHAM: Novan, Inc. has issued the following press release: Novan, Inc. (Nasdaq: NOVN) and its wholly owned subsidiary, EPI Health, LLC (collectively, 'the Company' or 'Novan'), today announced that it [...]

Published
2023

156. LIGAND OFFERS $15 MILLION TO ACQUIRE ASSETS OF NOVAN, INC

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-July 18, 2023--LIGAND OFFERS $15 MILLION TO ACQUIRE ASSETS OF NOVAN, INC. (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 17072023 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that [...]

Published
2023

157. Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Bankruptcy reorganizations, Drug approval, Pharmaceutical industry, Company bankruptcy, Banking, finance and accounting industries, Business
Abstract

DURHAM, Jul 17, 2023 (GLOBE NEWSWIRE via COMTEX) -- - The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. [...]

Published
2023

158. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 6, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 DEC 20 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

159. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Oct. 3, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 OCT 18 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

160. Ligand Pharmaceuticals Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities: (Sept. 25, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

161. Research team develops smallest antibody scaffold

Subjects
Ligand Pharmaceuticals Inc., Viral antibodies -- Health aspects -- Research, Antibodies -- Health aspects -- Research, Pharmaceutical industry -- Health aspects -- Research, Business, Health, Health care industry
Abstract

2023 OCT 8 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A collaborative scientific team led by researchers at the Applied [...]

Published
2023

162. Introducing Primrose Bio: Enabling Innovative Therapeutic Discovery and Manufacturing

Subjects
Ligand Pharmaceuticals Inc., Developing countries -- Health aspects, Vaccines -- Health aspects, Pharmaceutical industry -- Health aspects, Health
Abstract

2023 OCT 4 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production [...]

Published
2023

163. LIGAND'S PARTNER VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2B VOYAGE STUDY OF VK2809 IN PATIENTS WITH BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-May 17, 2023--LIGAND'S PARTNER VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2B VOYAGE STUDY OF VK2809 IN PATIENTS WITH BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 16052023 [...]

Published
2023

164. 10-Q: VIKING THERAPEUTICS, INC

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

Published
2023

165. LIGAND TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 4, 2023

Subjects
Ligand Pharmaceuticals Inc.
Abstract

ENPNewswire-April 25, 2023--LIGAND TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 4, 2023 (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 24042023 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) [...]

Published
2023

166. Ligand Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405]: (Feb. 29, 2024).

Subjects
CORPORATION reports, DRUGS, PHARMACEUTICAL biotechnology industry, BIOTECHNOLOGY industries
Abstract

Ligand Pharmaceuticals Inc., a biopharmaceutical company, has filed a Form 10-K with the U.S. Securities and Exchange Commission (SEC). The filing provides a comprehensive overview of the company's business and must be submitted within 90 days after the end of the fiscal year. The contact information for Ligand Pharmaceuticals Inc. is provided in the filing. This news article is a factual report and does not express any judgments or opinions. [Extracted from the article]

Published
2024

167. Ligand partners with CR Double-Crane to develop oral COVID-19 therapeutic using BEPro technology

Subjects
Ligand Pharmaceuticals Inc., General interest, News, opinion and commentary
Abstract

Global Banking News-October 22, 2021-Ligand partners with CR Double-Crane to develop oral COVID-19 therapeutic using BEPro technology (C)2021 ENPublishing - http://www.enpublishing.co.uk Biopharmaceutical company Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday awarded [...]

Published
2021

168. Ligand, CR Double-Crane in pact to make COVID-19 therapeutic with BEPro tech

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry -- Health aspects, Business, News, opinion and commentary
Abstract

Ligand Pharmaceuticals announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand's [...]

Published
2021

169. Ligand Pharmaceuticals Inc Annual Shareholders Meeting - Final

Subjects
Ligand Pharmaceuticals Inc., Stockholders, Business
Abstract

Presentation OPERATOR: Hello and welcome to the Annual Meeting of Stockholders of Ligand Pharmaceuticals Incorporated. Please note, today's meeting is being recorded. (Operator Instructions) It is now my pleasure to [...]

Published
2022

170. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jul. 10, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUL 26 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

171. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 21, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUL 5 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

172. Ligand price target raised to $180 from $174 at Barclays

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Barclays analyst Balaji Prasad raised the firm's price target on Ligand Pharmaceuticals to $180 from $174 and reiterates an Overweight rating on the shares after meeting with management. The analyst [...]

Published
2021

173. S&P Dow Jones to add Performance Food Group & Digital Turbine to S&P MidCap 400

Subjects
Performance Food Group Co., Ligand Pharmaceuticals Inc., TreeHouse Foods Inc., Cincinnati Bell Inc., Core-Mark Holding Company Inc., Dow Jones & Company Inc., Consumer goods industry, Telecommunications services industry, Newspaper publishing, Communications industry, Pharmaceutical industry, Telecommunications services industry, General interest, News, opinion and commentary
Abstract

Global Banking News-September 1, 2021-S&P Dow Jones to add Performance Food Group & Digital Turbine to S&P MidCap 400 (C)2021 ENPublishing - http://www.enpublishing.co.uk S&P Dow Jones Indices has announced it [...]

Published
2021

174. Ligand to replace Cincinnati Bell in S&P 600 at open on 9/7

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Macquarie Infrastructure (MIC) and Real Assets Inc. are acquiring Cincinnati Bell (CBB) in a deal pending final conditions. Ligand Pharmaceuticals (LGND) has a market capitalization that is more representative of [...]

Published
2021

175. Ligand's partner Gloria Biosciences gets China approval for Zimberelimab in cHL

Subjects
Ligand Pharmaceuticals Inc., Biological products, Monoclonal antibodies, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

The company states: 'Ligand Pharmaceuticals announced that its partner Gloria Biosciences has received approval from China's National Medical Products Administration or zimberelimab, an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment [...]

Published
2021

176. Ligand says Travere reporting 'impressive topline results' for sparsentan

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Ligand Pharmaceuticals (LGND) announces that its partner Travere Therapeutics (TVTX) announced 'positive' topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for [...]

Published
2021

177. 8-K: OmniAb, Inc

Subjects
Ligand Pharmaceuticals Inc., Cybernet Data Systems Inc., Computer services industry, Pharmaceutical industry, Computer services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- FALSE000184625300018462532023-03-302023-03-300001846253us-gaap:CommonStockMember2023-03-302023-03-300001846253us-gaap:WarrantMember2023-03-302023-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

Published
2023

178. LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-February 23, 2023--LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 22022023 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported [...]

Published
2023

179. Ligand's Partner Travere Therapeutics Announced FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Proteinuria -- Development and progression, Immunoglobulin A, Immunotherapy, Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI [...]

Published
2023

180. Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI[TM] (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Proteinuria, Endothelin, Immunoglobulin A, Immunotherapy, Drug approval, Pharmaceutical industry, Business, Business, international
Abstract

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a [...]

Published
2023

181. LIGAND TO REPORT FOURTH QUARTER FINANCIAL RESULTS ON FEBRUARY 22

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-February 7, 2023--LIGAND TO REPORT FOURTH QUARTER FINANCIAL RESULTS ON FEBRUARY 22 (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 06022023 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 [...]

Published
2023

182. LIGAND'S PARTNER NOVAN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR BERDAZIMER GEL, 10.3% FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-January 9, 2023--LIGAND'S PARTNER NOVAN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR BERDAZIMER GEL, 10.3% FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 06012023 [...]

Published
2023

183. Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-January 9, 2023--Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- [...]

Published
2023

184. Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Molluscum contagiosum -- Drug therapy, Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Ligand Pharmaceuticals Incorporated announced that its partner Novan, Inc., has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for [...]

Published
2023

185. Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Molluscum contagiosum -- Drug therapy, Drug approval, Business, Business, international
Abstract

Potential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million [...]

Published
2023

188. Ligand price target lowered to $190 from $198 at Barclays

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Barclays analyst Balaji Prasad lowered the firm's price target on Ligand Pharmaceuticals to $190 from $198 and keeps an Overweight rating on the shares following the company's Q1 results. The [...]

Published
2021

189. Q3 2021 Ligand Pharmaceuticals Inc Earnings Call - Final

Subjects
Ligand Pharmaceuticals Inc., Pharmaceutical industry, Business, Evomela (Medication), Vaxneuvance (Vaccine)
Abstract

Presentation OPERATOR: Good day, and thank you for standing by. Welcome to the Ligand Pharmaceuticals' Third Quarter Earnings Call. (Operator Instructions) I would now like to hand the conference over [...]

Published
2021

190. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jun. 13, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

191. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 18, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 JUN 7 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

192. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 12, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

193. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (May 10, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 24 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

194. Ligand Pharmaceuticals Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements: (Apr. 20, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

195. Ligand Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order: (Apr. 26, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

196. Ligand Pharmaceuticals Inc. Files SEC Form ARS, Annual Report To Security Holders: (Apr. 20, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

197. Ligand Pharmaceuticals Inc. Files SEC Form SC 13D/A, General Statement of Acquisition of Beneficial Ownership: (Mar. 30, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 APR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

198. Ligand Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Mar. 28, 2023)

Subjects
United States. Securities and Exchange Commission, Ligand Pharmaceuticals Inc., Pharmaceutical industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2023 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results